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Objectives. We estimated HIV prevalence rates among young adults in the
United States.
Methods. We used survey data from the third wave of the National Longitudi-
nal Study of Adolescent Health, a random sample of nearly 19000 young adults
initiated in 1994–1995. Consenting respondents were screened for the presence
of antibodies to HIV-1 in oral mucosal transudate specimens. We calculated prev-
alence rates, accounting for survey design, response rates, and test performance.
Results. Among the 13184 participants, the HIV prevalence rate was 1.0 per
1000 (95% confidence interval [CI]=0.4, 1.7). Gender-specific prevalence rates
were similar, but rates differed markedly between non-Hispanic Blacks (4.9 per
1000; 95% CI=1.8, 8.7) and members of other racial/ethnic groups (0.22 per 1000;
95% CI=0.00, 0.64).
Conclusions. Racial disparities in HIV in the United States are established early
in the life span, and our data suggest that 15% to 30% of all cases of HIV occur
among individuals younger than 25 years. (Am J Public Health. 2006;96:1091–1097.
doi:10.2105/AJPH.2004.054759)
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The estimated incidence of both AIDS and
HIV in the United States is believed to be
fairly stable after having fallen for several
years subsequent to the initial crest of the epi-
demic.1,2 In contrast, the prevalence of AIDS
continues to rise as treatment extends survival
rates among individuals with HIV. According
to Centers for Disease Control and Prevention
(CDC) estimates, more than 174000 people
in the United States were living with HIV
(without AIDS) as of December 2003, and
another 400000 were living with AIDS.1
On the basis of the age distribution of cases
identified through AIDS surveillance systems,
estimates suggest that as many as half of all
infections occur among individuals younger
than 25 years.3,4 CDC data indicate a rela-
tively balanced gender ratio but a large racial
disparity among young people with HIV:
41% of 13- to 24-year-olds reported to the
CDC HIV surveillance system in 2001 were
young women (no other age group exhibited
a larger female share of infection); 56% were
non-Hispanic Blacks, as compared with 15%
of the general population.5
The current data available on HIV preva-
lence rates among young people are subject
to several limitations. CDC surveillance data
on HIV prevalence in the United States are
steadily improving but remain incomplete,
and they are not well suited to estimating
prevalence rates among young adults. The
CDC surveillance system identifies only those
who choose to be tested for HIV and those
who fit screening profiles. Surveys indicate
that the testing rate outside of the populations
at highest risk remains below 50%.6 Testing
also appears to occur late in the course of
infection: 20% of patients are diagnosed with
HIV and AIDS in the same calendar month
and approximately 40% in the same year.7
Because HIV infection typically precedes
AIDS by about 10 years, this suggests that
many individuals are infected well before
their HIV diagnosis is recorded and that young
people may be underrepresented in surveil-
lance data. Finally, the system does not in-
clude all states or regions and thus may not
provide representative data.
Alternative sources of data on HIV infec-
tion among young people include back calcu-
lation (imputing dates of infection from dates
of AIDS diagnosis) and surveys. Back calcula-
tion from incident AIDS cases has become
less feasible with the increasingly widespread
use of antiretroviral therapy, and the most
recent reliable back-calculation estimates are
now a decade old.8 Population-based surveys
require very large samples to provide reliable
estimates for low-prevalence populations.
Data are available from only one such US
survey, the National Health and Nutrition
Examination Survey (NHANES). NHANES
was primarily designed to estimate HIV prev-
alence rates among adults and thus involved
a relatively small sample of young people (ap-
proximately 1500 cases).
Wave III of the National Longitudinal
Study of Adolescent Health (Add Health), a
nationally representative, population-based
survey, was designed to provide estimates of
HIV prevalence rates among 19- to 24-year-
olds in the United States. The third wave of
Add Health, conducted in 2001–2002, sur-
veyed approximately 14000 young adult
men and women. These data, which we ex-
amined in this study, provide the first general
population estimates of the prevalence of
HIV by gender and race among US young
adults. In addition, Add Health’s longitudinal
design offered a unique opportunity to
prospectively assess the nature of nonre-
sponse in a survey context, in that people
who dropped out in later waves had informa-
tion available from earlier waves that could
be used in such assessments.
METHODS
Design and Participants
Add Health was designed to assess the
health status of adolescents and explore the
causes of their health-related behaviors. Three
waves of data were collected: wave I during
September 1994 through December 1995,
wave II during April through August 1996,
and wave III during August 2001 through
April 2002. The primary sampling unit for the
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original survey was the school, and the study
design ensured that the sample was represen-
tative of US schools with respect to region of
the country, urbanism, school type, ethnicity,
and school size. The wave I representative
sample comprised 18924 participants; tar-
geted oversampling ensured substantial repre-
sentation of non-Hispanic Blacks, Hispanics,
Asian Americans, and Native Americans (for
additional details on the study design, see
http://www.cpc.unc.edu/projects/addhealth).
The wave III sample consisted of 14322
wave I participants located and reinterviewed
during the fieldwork period (75.7% response
rate). The great majority of respondents were
interviewed at home; if this was not possible,
every attempt was made to interview them
in their current location. For example, to the
extent that permission was obtained by local
authorities and prison officials and confiden-
tiality of the interview could be ensured, re-
spondents were interviewed at military bases,
penitentiary facilities, and other institutions.
Before beginning, the interviewer described
the wave III interview and obtained consent
for participation. Completion of the interview
was not linked to a requirement to provide a
biospecimen. At the end of the interview, re-
spondents were asked to independently con-
sent to and provide (with an incentive pay-
ment of $10) an oral mucosal transudate
(OMT) specimen for HIV testing.
Here we report prevalence estimates strati-
fied according to self-reported gender and
race. We collapsed race into 2 categories: non-
Hispanic Black and other. This unfortunate
limitation was necessitated by the small num-
ber of HIV-positive cases observed and the
reporting rules designed to protect respondent
confidentiality. Respondents who reported
“Black or non-Hispanic Black” as their only or
primary race and did not report Hispanic ori-
gin were classified as non-Hispanic Black.
Specimen Collection and Testing
The OraSure HIV-1 Oral Fluid Specimen
Device (OraSure Technologies, Bethlehem, Pa)
was used in collecting OMT specimens. The
collection device was then placed in the vial
supplied with the kit and shipped to the lab-
oratory facility in a plastic bag. The Oral
Fluid Vironostika HIV-1 Microelisa System
(Organon Teknika Corp, Durham, NC) was
used in testing eligible OMT samples for the
presence of HIV-1 antibodies.
OMT specimens with a negative enzyme-
linked immunosorbent assay (ELISA) result
after initial testing were reported as negative,
as were specimens that were reactive on the
initial run but for which both duplicate repeat
tests were negative and specimens repeatedly
reactive according to ELISA but demonstrat-
ing no bands after Western blot testing. OMT
specimens that were repeatedly reactive ac-
cording to ELISA and met the criteria for a
positive Western blot were reported as posi-
tive. OMT specimens that were repeatedly
reactive after ELISA testing but did not dem-
onstrate a banding pattern meeting the crite-
ria for a positive Western blot were reported
as indeterminate.
Statistical Analyses
Use of a diagnostic test in a survey context
gives rise to 2 sources of uncertainty in esti-
mates: measurement error because of test in-
accuracy and potential sample bias. The
OMT assay is a highly accurate test, with a re-
ported sensitivity of 98.80% and a specificity
of 99.86%.9 Because the performance of the
test is not known with certainty, we combined
estimates from the one published study9 on
its performance with the results from Add
Health to estimate prevalence, sensitivity, and
specificity jointly using maximum likelihood
analyses and standard adjustments for test
performance. We used bootstrap resampling
to calculate 95% confidence intervals10 based
on quantiles from 1000 resamples.11
As a national survey involving a probability
sample, Add Health was designed to be used
for general population inference, but some
limitations should be noted. For example, the
original wave I sample frame consisted only
of 7th- through 12th-grade adolescents in-
cluded on school registers. Also, the response
rate in wave I was 78.9%, and nonrespon-
dents in wave I were not eligible for future
waves (although nonrespondents in later
waves were). The impact of the school enroll-
ment criterion on a wide range of risk-related
behaviors appeared to be relatively small,12
and, as a result of the longitudinal design,
the wave III sample included several hundred
high school dropouts. However, the adoles-
cents at highest risk (e.g., runaways and
homeless youth) were still not likely to be in-
cluded in the survey. Our results should not
be extrapolated to this group, but its absence
is unlikely to have influenced our general
population estimates.
Poststratification weights were developed
by the Add Health research team to correct
for cumulative differences in survey participa-
tion according to race, gender, and original
grade level.13 We used these weights to adjust
for unbiased nonresponse in wave III. If sur-
vey participation or specimen provision was
less likely among groups with higher rates of
HIV infection, however, our data would still
underestimate true prevalence rates. This is
the most challenging type of nonresponse to
address in survey contexts, but the longitudi-
nal design of Add Health provided a unique
opportunity to do so by comparing the char-
acteristics of respondents who did and did
not provide specimens in the third wave of
the study. More than 99% of those who did
not provide specimens in wave III had infor-
mation available on HIV-related risk behav-
iors in earlier survey waves. We used this
information and a sensitivity analysis to ex-
amine the potential effects of biased non-
response on our prevalence estimates.
We used SPSS14 in conducting descriptive
analyses. We calculated prevalence estimates
and confidence intervals and made sensitivity
projections using the R statistical package.15
RESULTS
Study Population
In all, 14322 individuals were interviewed
in the wave III survey (75.7% of the eligible
wave I sample), and specimens from 13184
of the interviewed participants were available
for HIV testing (92.1% of wave III partici-
pants, 69.7% of the eligible wave I sample).
About one quarter of the interview non-
response in wave III was because of individu-
als refusing to take part (n=1109; 6%); the
remaining nonrespondents (n=3493; 18%)
could not be located or were unable to partic-
ipate for other reasons. Among those who
participated, 769 (5.4%) refused to be tested
for HIV, and 369 (2.7%) of the specimens
obtained could not be processed owing to
shipping or laboratory problems. Response
rates were slightly higher among young
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TABLE 1—Demographic Characteristics of the Add Health Wave III Sample: 2001–2002
(n=14322)
No. Unweighted %a Weighted %b
Gender
Men 6767 47.2 50.8
Women 7555 52.8 49.2
Race/ethnicity
White 7741 54.0 67.5
Hispanic 2340 16.3 11.8
Non-Hispanic Black 3042 21.2 16.0
Asian American 1026 7.2 3.7
Native American 136 0.9 0.8
Age, y
18–19 1453 10.1 12.7
20–21 4123 28.8 32.3
22–23 5520 38.5 32.1
24–25 3101 21.7 21.7
≥ 26 125 0.9 1.2
Region
West 3685 25.7 17.7
Midwest 3328 23.2 28.7
South 5506 38.5 40.2
Northeast 1790 12.3 13.4
aPercentage in the study sample.
bPercentage in the target US population.
TABLE 2—Estimated HIV Prevalence Rates Among Young Adults: United States, 2001–2002
Estimated Prevalence Estimated No. of 
(per 1000) (95% CI) Cases (95% CI)
Gender 
Men 1.06 (0.25, 2.19) 11 954 (2 803, 24 471)
Women 0.87 (0.26, 1.63) 9 432 (2 787, 17 631)
Race/ethnicity
Non-Hispanic Black 4.92 (1.84, 8.70) 17 275 (5 810, 30 477)
Other 0.22 (0.00, 0.64) 4 112 (0, 11 724)
Overall 0.97 (0.40, 1.70) 21 387 (8 688, 37 532)
Note. CI = confidence interval.
women than young men and varied modestly
by race (range: 72%–78%). Although the
overall age range was 18 to 28 years, 93% of
the participants were between 19 and 24
years old. Table 1 shows the demographic
breakdown of the sample.
HIV Prevalence
Fifteen specimens tested positive for HIV, 8
were indeterminate, and the remainder were
negative. The indeterminate cases appeared to
be randomly distributed in the sample and
were removed from further analyses. After
correction for the sensitivity and specificity of
the Orasure test, the estimated overall HIV
prevalence was about 1 per 1000 (Table 2),
with slightly higher rates among young men
and a striking racial disparity: of the 15 posi-
tive tests, 12 were among non-Hispanic Black
respondents. These results correspond to esti-
mated prevalence rates of 4.9 per 1000
among non-Hispanic Blacks and 0.2 per 1000
in the remaining population, a 20-fold gap.
Overall, the estimated number of HIV-infected
individuals in this age group (projected with
the Add Health sample weights) is 21400
(17300 non-Hispanic Blacks and 4100 mem-
bers of the remaining population).
To investigate whether biased nonresponse
affected these estimates, we examined data
from earlier waves of the study. We used
4 indicators of male same-sex attraction or
activity and a question on injection drug use
from wave II. We examined each question in-
dependently and as a cumulative sum. We
found no significant differences between re-
sponders and nonresponders. We also con-
structed an index designed to capture 2 key
elements of general sexual exposure: lifetime
number of sex partners, reported from the first
2 waves (including both same- and opposite-
sex partners), and gross variations in local
HIV prevalence rates. On this index, number
of partners was multiplied by a prevalence
factor of 1 (rural), 2 (suburban), or 5 (urban),
reflecting urban–rural prevalence differences
in CDC AIDS surveillance statistics.16
Participants who provided specimens in
wave III and participants who refused (either
the interview or the test) did not differ signifi-
cantly in their level of potential sexual expo-
sure to HIV (Figure 1). Potential exposure
was significantly higher among those who
were not included for reasons other than re-
fusal (“other reasons” in Figure 1). The mean
difference, although statistically significant,
was only 21%. As an example of its potential
impact, the prevalence among nonrespon-
dents would have to have been 5 times
higher than that among respondents to dou-
ble our population estimate. A prevalence
differential on the order of the 21% exposure
difference observed here would have virtually
no effect on our estimate.
We compared these findings with pub-
lished estimates from other large, nationally
representative data sources. The only other
representative household-based survey in
which HIV status was ascertained was
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Note. Shown are means and 95% confidence intervals (CIs) for the wave I and wave II cumulative sexual exposure indexes for
3 groups of Add Health survey participants: those who provided a usable specimen in wave III, those who participated in
earlier waves but refused either the interview or the HIV test in wave III, and those who participated in earlier waves but either
were not interviewed for other reasons in wave III or provided an unusable specimen. Number of sexual partners (both male
and female) was multiplied by a prevalence differential factor for location (1 = rural, 2 = semiurban, 5 = urban) to estimate
sexual exposure (see “Results” for details).
FIGURE 1—Add Health wave I and wave II cumulative sexual exposure index differentials, by
response status in wave III.
NHANES. Both NHANES III (1988–1994)
and the more recent NHANES rolling survey
(1999–2002) involved wider age ranges than
Add Health for the tested samples (18–59
and 18–49 years, respectively).17,18 The data
for the rolling survey can be broken down to
the 19- to 24-year age range, but this limits
the sample to about 1500 respondents and
only one case involving an HIV-positive test;
thus, we used the full sample in our compari-
son. The most recent back-calculation esti-
mates based on AIDS incidence data cover
an age range closer to that of Add Health
(18–22 and 23–27 years), but these esti-
mates date to 1993.19
Estimates from the CDC surveillance sys-
tem allow for the closest match with the pres-
ent data, with a similar age range and time
(20–24 years in 2001) as well as an age
range selection allowing for a comparison
with NHANES (20–59-year-olds).5 At that
time, the system excluded a number of im-
portant areas, including California, and had
included New York for only 1 year. The CDC
system is designed to measure incident rather
than prevalent cases of HIV, so we con-
structed the standard proxy for prevalent HIV
infections by summing cumulative HIV infec-
tions and AIDS cases and subtracting cumula-
tive AIDS deaths. Because information on
degree of population coverage was not avail-
able, we did not attempt to calculate preva-
lence rates from the CDC data.
Given the fundamental differences in the
sources of data we used in our comparisons,
the degree of consistency in the total numbers
of cases estimated among young adults was
surprising (Table 3). Both the back-calculation
and CDC estimates for this population were
within the confidence interval for the Add
Health estimate, although the Add Health
estimate itself was about 50% lower. The
NHANES estimates, derived from a substan-
tially wider age range, were naturally much
higher than those of Add Health, but they
were similar in magnitude to the CDC esti-
mate for that age range.
Group-specific estimates were mixed: These
estimates were consistent for women and
non-Hispanic Blacks but less consistent for
men and individuals from other racial/ethnic
groups. The Add Health, back-calculation,
and CDC estimates for women were very
close, in terms of both numbers of cases and
prevalence rates. This was the case as well
among non-Hispanic Blacks. Among men,
however, the Add Health estimates were
about half the comparable back-calculation
and CDC estimates, and the number of cases
estimated for individuals in the Add Health
“other” race/ethnicity category was less than
one quarter the number obtained from the
other data sources. In Add Health, the race
gap in HIV prevalence rates was estimated
to be approximately 20:1 (Table 3). The next
closest estimate, about 10:1, was derived
from the NHANES rolling survey, and the
back-calculation estimate for a decade earlier
was approximately 5:1.
DISCUSSION
The Add Health results suggest that the
prevalence rate of HIV among young adults
in the United States is approximately 1 per
1000. Rates of infection are slightly higher
among young men than among young
women, and there are large differences be-
tween non-Hispanic Blacks and members of
other racial/ethnic groups. The Add Health
estimates were lower than those of other data
sources for men and for members of racial/
ethnic groups other than non-Hispanic Black.
How well did this survey capture the true
prevalence rate among young adults? Al-
though the number of HIV cases in the Add
Health sample was too small to support a
multivariate analysis of HIV determinants,
the substantial amount of data available from
the large overall sample allowed for evalua-
tion of possible biases and sources of error in
estimates of prevalence rates.
Diagnostic test performance characteristics,
for example, were unlikely to have compro-
mised the findings reported here. Given the
low overall prevalence rate in this sample,
any bias in estimates would be dominated by
the specificity (rather than the sensitivity) of
the HIV test, and the effect would be to in-
flate prevalence estimates with false positives.
The Add Health estimates, however, do not
appear to be too high, suggesting that the
test’s performance had little impact.
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TABLE 3—Comparisons of Add Health HIV Prevalence Estimates With Estimates From Other Data Sources
NHANES: NHANES:
Add Health: 2001–2002 Back Calculation: 1993 CDC Surveillance: 2001 1988–1994 1999–2002
(19–24-Year-Oldsa) 18–22- 23–27- 20–24- 20–59- (18–59- (18–49-
(95% Confidence Interval) Year-Olds Year-Olds Year-Olds Year-Olds Year-Olds) Year-Olds)
No. of cases
Total 21 387 (8 688, 37 532) 33 100 116 000 36 252 537 106 461 000 540 060
Male 11 954 (2 803, 24 471) 22 100 88 500 23 494 413 153 368 000 402 002
Female 9 432 (2 787, 17 631) 11 000 27 500 12 758 123 953 94 000 138 058
Non-Hispanic Black 17 275 (5 810, 30 477) 16 000 49 200 18 179 238 193 189 000 319 387
Other race/ethnicity 4 112 (0, 11 724) 17 100 66 800 18 073 298 913 273 000 220 672
Prevalence per 1000
Total 0.97 (0.40, 1.70) 1.98 6.54 . . . . . . 3.20 4.26
Male 1.06 (0.25, 2.19) 2.60 9.92 . . . . . . 5.20 6.40
Female 0.87 (0.26, 1.63) 1.34 3.12 . . . . . . 1.30 2.16
Non-Hispanic Black 4.92 (1.84, 8.70) 6.42 19.99 . . . . . . 11.00 21.37
Other race/ethnicity 0.22 (0.00, 0.64) 1.20 4.37 . . . . . . 2.11 1.97
Note. CDC = Centers for Disease Control and Prevention; NHANES = National Health and Nutrition Examination Survey.
aThe full sample age range was 18 to 28 years, but 93.2% of the participants were 19 to 24 years of age.
Random sampling variability was also un-
likely to have played a major role in the find-
ings described here because, although the
number of cases observed was small, the
overall sample size was quite large. If the true
prevalence rate were actually 2 in 1000
(twice our estimate), the odds of drawing a
sample such as ours at random would be ap-
proximately 1000 to 1. Factoring in the prob-
able geographic clustering of HIV and the full
initial clustering of the wave I sample, the
odds might rise to 2 in 100. The cluster sam-
pling effect was likely to be smaller, however,
in that nearly 70% of participants had moved
since their first interview.
This leaves the question of systematic bi-
ases in the sample population. Several empiri-
cal indicators suggest that the Add Health
wave III sample was not systematically biased
with respect to potential HIV exposure. These
indicators include longitudinal evidence that
wave III participants were similar to nonpar-
ticipants on a broad range of HIV-related
risk behaviors during their teenage years, the
fact that rates of other sexually transmitted
infections in the wave III sample were consis-
tent with existing estimates,20,21 and the fact
that the estimates for non-Hispanic Blacks—
the sample subgroup most likely to be af-
fected by underrepresentation of high-risk
incarcerated populations—were comparable to
those derived from other data sources.
School dropouts were not included in the
original sample frame, but those who
dropped out of school between wave I (1995)
and wave III (10 years later) were followed,
and thus several hundred dropouts were in-
cluded in the sample described here. Finally,
although our sample slightly overrepresented
the South and underrepresented the other
three study regions, the effect on our overall
prevalence estimates was likely to be small.
Recent CDC data suggest that the South and
Northeast are the epicenters of HIV infection
among young people.22 If this is true, then the
present regional imbalance might have had
little impact, because the Add Health sample
percentage in these 2 regions combined
(50%) was very close to the population per-
centage (49% in the 2000 census).
The preceding does not mean that non-
response in the Add Health survey was en-
tirely unbiased with respect to HIV. Other
mechanisms might have been at work, and
the previous wave information used here
was gathered 5 years earlier and thus may
not have reflected respondents’ risk status at
wave III. Taken together, however, our data
suggest that if the Add Health wave III
sample estimates for men in the “other”
race/ethnicity category are too low, the
mechanism is specific to HIV status and
race. On balance, our results indicate that
population-based surveys can be used to ob-
tain estimates of national HIV prevalence
rates, even in low-prevalence settings. As
back calculation becomes less reliable and
HIV testing methods become simpler, popu-
lation-based survey data can become a reli-
able means of HIV surveillance.
Beyond surveillance, the findings reported
here have 2 implications for understanding
the HIV epidemic in the United States. First,
both the Add Health–NHANES comparison
and the CDC estimates shown in Table 3
imply that there are roughly 20 times more
cases among 20- to 59-year-olds than among
individuals younger than 25 years. The size
of this differential is not consistent with the
widely cited estimate that half of all infections
occur among those younger than 25 years.3
If we take Table 3’s Add Health and CDC
estimates among young adults as a constant
baseline and project them forward, assuming
an exponential 12-year average survival pe-
riod (12 years is the value used in the Rosen-
berg estimate8), then a rough approximation
of the equilibrium number (i.e., the point at
which the number of infections among those
younger than 25 years and the number
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among those aged 20–59 years are constant)
of individuals 20 to 59 years old who con-
tracted HIV before the age of 25 years would
be 80000 to 160000 (according to the Add
Health and CDC estimates, respectively).
Comparing this estimate with the CDC total
of about 540 000 HIV infections among
20- to 59-year-olds (Table 3) suggests that
only 15% to 30% of infections are acquired
before the age of 25 years. Raising the aver-
age survival time to 30 years would increase
the estimated percentage of individuals con-
tracting HIV before 25 years of age to 20%
to 45% at equilibrium.
In both survival scenarios, however, ap-
proximately 35 years is required to reach
equilibrium, and before that the estimated
percentage of individuals contracting HIV
before the age of 25 years is substantially
lower. This difference in estimates could re-
flect real changes in the age distribution of
HIV incidence in the past 10 years, or it
might be the result of changes in measure-
ment of HIV and AIDS. Given that it has
implications for targeting prevention efforts,
this topic deserves more study.
Second, our findings show that the well-
known racial disparities in HIV infection in
the United States are established early in the
life span. Although our estimate of a 20-fold
prevalence gap between non-Hispanic Blacks
and members of other racial/ethnic groups
appears high relative to the back-calculation
estimates shown in Table 3, it is consistent
with the 19-fold estimate based on CDC data
on incident cases in 2000.5 It also parallels
the large racial differentials evident in the
prevalence rates of other sexually transmitted
infections: In 2000, rates of gonorrhea were
24 times higher among non-Hispanic Black
youths than among White youths, rates of
syphilis were 30 times higher,23 and rates of
chlamydia23 and herpes simplex virus
type 224 exhibited significant (although
smaller) racial disparities.
Race is likely to be a proxy for a number of
factors that influence risk exposure, including
discrepancies in health care access, differ-
ences in sexual behavior, genetic differences,
and the structure of partnership networks.
The relative importance of each of these fac-
tors in determining racial disparities in HIV
prevalence rates is gradually becoming clear.
The stability of race differentials has been
shown to persist after control for socioeco-
nomic status25 and number of sexual part-
ners,26 remaining strong even in the case of
young people who enter juvenile detention
facilities27 and inject drugs.28
This evidence suggests that, although pov-
erty and behavioral differentials may matter,
they do not account alone for the race dispar-
ities observed in HIV prevalence rates. There
has been no proposed mechanism by which
genetic differences might influence suscepti-
bility or infectivity, and there is no current
evidence pointing to such a mechanism. The
mechanism of sexual networks, by contrast, is
both conceptually clear and empirically estab-
lished: People are infected by their partners,
who in turn are infected by their partners.
“Networks” is simply the term that refers to
these direct and indirect connections that sus-
tain transmission.29
Recent studies have shown that sexual net-
works tend to display a pattern of “assortative
mixing,” segregating along race, class, and ge-
ographic lines. Among non-Hispanic Blacks,
race, poverty, and geographic clustering result
in higher prevalence rates of sexually trans-
mitted diseases among potential partners,30
raising the probability of exposure to infec-
tion.31 When partnerships overlap in time—a
pattern labeled “concurrency”—the connectiv-
ity of a sexual network increases, and trans-
mission of sexually transmitted infections is
amplified.32–34 Concurrency is more common
among non-Hispanic Blacks than among
other groups,35,36 so this may further amplify
the spread of infection in these relatively seg-
regated networks.
In summary, although the prevalence of
HIV among young adults in the United
States appears to be relatively low, the bur-
den is inequitably distributed by race. The
cumulative body of research over the past
decade suggests that the pervasive racial
differentials in rates of sexually transmitted
infections are induced by the structure of
partnership networks: Assortative mixing
segregates networks according to race, geog-
raphy, and class, concentrating the effects of
both economic disadvantage and concurrent
partnerships.
The implications for HIV research and pre-
vention are clear. We need to better under-
stand the ways in which networks influence
the transmission dynamics of HIV, given that
small differences in behavior can have large
(nonlinear) effects on network connectivity.
Moreover, because people’s risk depends on
the behavior of their partners, we need to
better understand the relational context of
HIV risk behavior; individual knowledge and
attitudes are only part of the solution. Unless
and until a sterilizing HIV vaccine becomes
available, reducing disparities in HIV preva-
lence rates—both within and between coun-
tries—requires a better understanding of the
links between individual behavior, partner-
ship dynamics, and transmission networks.
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help public health practitioners improve
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ent audiences. Covering all modes of
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practical, real-world recommendations
and examples of how to communicate
public health information to nonscientific
audiences more effectively. The knowl-
edge and skills gleaned from this book
will assist with planning and executing
communication activities commonly done
by public health practitioners.
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